



# Cibles Thérapeutiques et conception de médicaments

## Rapport Hcéres

### ► To cite this version:

Rapport d'évaluation d'une entité de recherche. Cibles Thérapeutiques et conception de médicaments. 2018, Université Paris Descartes, Centre national de la recherche scientifique - CNRS. hceres-02031860

**HAL Id: hceres-02031860**

**<https://hal-hceres.archives-ouvertes.fr/hceres-02031860>**

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

REPORT ON THE RESEARCH UNIT:  
Cibles Thérapeutiques et Conception de  
Médicaments

UNDER THE SUPERVISION OF THE  
FOLLOWING INSTITUTIONS AND  
RESEARCH BODIES:

Université Paris Descartes  
Centre National de la Recherche Scientifique -  
CNRS

**ÉVALUATION CAMPAIGN 2017-2018**  
GROUP D



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the expert committee<sup>2</sup>:

Adriaan IJzerman, Chairman of the  
committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

## UNIT PRESENTATION

<b>Unit name:</b>	Cibles Thérapeutiques et Conception de Médicaments
<b>Unit acronym:</b>	CiTCoM
<b>Requested label:</b>	UMR + ERL
<b>Application type:</b>	Restructuration
<b>Current numbers:</b>	UMR 8015 and UMR 8638
<b>Head of the units (2017-2018):</b>	Mr Nicolas LEULLIOT and Mr Olivier LAPREVOTE
<b>Project leader (2019-2023):</b>	Mr Nicolas LEULLIOT
<b>Number of teams:</b>	7

## COMMITTEE MEMBERS

<b>Chair:</b>	Mr Adriaan IJZERMAN, Leiden University, Netherlands
<b>Experts:</b>	Ms Martine CADENE, CNRS, Orléans
	Mr Karl GADEMANN, University of Zurich, Switzerland
	Mr Hervé KOVACIC, Université d'Aix-Marseille (representative of CNU)
	Mr Sylvain LACLEF, Université de Picardie (supporting personnel)
	Mr Roland MARQUET, Université de Strasbourg (representative of CoNRS)
	Ms Christa MUELLER, Universität Bonn, Germany
	Ms Eva PEBAY-PEYROULA, Université Grenoble Alpes
	Ms Natacha ROCHEL, Université de Strasbourg
	Mr Didier ROGNAN, Université de Strasbourg (representative of CoNRS)
<b>HCERES scientific officer:</b>	Mr Georges MASSIOT
<b>Representatives of supervising institutions and bodies:</b>	Mr Jean Louis BEAUDEUX, Université Paris Descartes
	Mr Erick DUFOURC, CNRS
	Ms Karine GIOVANNANGELI, Inserm

Ms Christine GUILLARD, Inserm

Mr Hughes LORTAT JACOB, CNRS

Mr Stephano MARULLO, Université Paris Descartes

Mr Marius RÉGLIER, CNRS

## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The future laboratory results from the merging of two well-established laboratories from University René Descartes: the "Laboratoire de Cristallographie et RMN Biologiques" (LCRB) and the "Chimie Organique, Médicinale et Extractive et Toxicologie Expérimentale" unit (COMETE) both associated with the CNRS, INSB and INC, respectively. These laboratories are located on the premises of the Faculty of Pharmacy, "rue de l'Observatoire", in part in renovated areas but mostly in premises that would require renovation.

### MANAGEMENT TEAM

The unit will be directed by Mr Nicolas LEULLIOT (Paris Descartes), with Ms Isabelle BROUTIN and Mr Philippe BELMONT as deputy directors.

### HCERES NOMENCLATURE

SVE2-1; ST4-1; ST4-3; ST4-4.

### SCIENTIFIC DOMAIN

The old laboratories and the new unit have expertise in, and will focus on, integral aspects of the drug discovery process, including chemistry (natural products, synthetic and medicinal chemistry, analytical chemistry including metabolomics), computational approaches (molecular modelling), biology (biochemistry, structural biology), pharmacology (mechanisms of (inter)action, pharmacokinetics), drug delivery (biopharmaceutics, formulation), and toxicology.

### UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
<b>Permanent staff</b>		
Full professors and similar positions	11	11
Assistant professors and similar positions	34.6	32.6
Full time research directors (Directeurs de recherche) and similar positions	4	5
Full time research associates (Chargés de recherche) and similar positions	5.9	7.9
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	1	1
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	18.5	17.5
<b>TOTAL permanent staff</b>	<b>75</b>	<b>75</b>
<b>Non-permanent staff</b>		
Non-permanent professors and associate professors, including emeritus	5	

Non-permanent full time scientists, including emeritus, post-docs	7	
Non-permanent supporting personnel	1	
PhD Students	21	
<b>TOTAL non-permanent staff</b>	<b>34</b>	
<b>TOTAL unit</b>	<b>109</b>	

## GLOBAL ASSESSMENT OF THE UNIT

The proposed unit aims to become a high-performing research department covering most of the drug discovery pipeline. The integration process may be the first step in a further restructuring of the Paris Descartes Faculty of Pharmacy's research into two more research departments. If successful, it will surely improve the visibility of the research performed in this section of the School of Pharmacy and may help in attracting young talent from elsewhere as well as additional funding, from both public and private partners. The seven teams involved in the project are complementary, constitute a good mix of fundamental and applied science, and are well positioned to develop strongly supportive technology platforms and core facilities for researchers in- and outside of the unit. On the average, they all have a very good scientific production, with some items of excellence. All PIs have national visibility and a few of them are internationally known. They are able to collect money from national agencies and charities and their training of students is very good. Our discussions with the PIs of the new research department were informative and inspiring, providing credit to a true desire of turning the new unit into a success. At this early stage there are no joint research outcomes yet; therefore, the committee can only conclude that the department's ambition and objectives are well defined and provide a clear path forward for the 2019-2023 term. In view of the anticipated development of additional core facilities, the infrastructure of the new unit needs further attention.

The evaluation reports of Hceres  
are available online : [www.hceres.com](http://www.hceres.com)

**Evaluation of clusters of higher education and research institutions**

**Evaluation of higher education and research institutions**

**Evaluation of research**

**Evaluation of doctoral schools**

**Evaluation of programmes**

**International evaluation and accreditation**



2 rue Albert Einstein  
75013 Paris, France  
T. 33 (0)1 55 55 60 10

[hceres.com](http://hceres.com)

[@Hceres\\_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)